Antibiotic guideline in Adult Cystic Fibrosis
|
|
- Russell Rose
- 6 years ago
- Views:
Transcription
1 Antibiotic guideline in Adult Cystic Fibrosis Choice of antibiotics in cystic fibrosis is based on several facts including ganism sensitivity, histy of adverse reactions allergy and severity of symptoms. In most cases, at least two antibiotics are prescribed together in der to limit the emergence of super-infection with resistant strains pathogens which may be present in sputum but not consistently present on culture. The incidence of Closdtridium difficile in CF is low, so the restriction on use of drugs which commonly cause antibiotic related diarrhoea in other patient groups is less critical. Most patients should be prescribed at least two antibacterial agents in combination. These may be given ally, intravenously in combination. The al route is usually acceptable where available and absption not a concern. Several of the agents are only available parenterally and patients will nmally be trained to self-administer, often using a Totally Implantible Intravenous Access Device (TIVAD). In patients colonised by multiple pathogens often a third ( me) antibiotic may be required. Specialist advice is required in complex cases. Antibiotic regimens should be based on sputum sensitivity results, however a response is often observed despite in vitro resistance. Synergy testing may be useful to guide antimicrobial choice where multi-resistant ganisms are cultured. Treatment regimens should be tailed to maximise individual patient needs in der to maximise adherence and minimise adverse effects. This is a guideline only and individual patient facts should be considered when selecting treatment, including: Interactions should be checked, especially in post-transplant patients who will be taking immunosuppressant drugs Low body weight patients, under 50kg may require a dose reduction Doses may need to be reduced in renal impairment Histy of allergic reactions intolerances is me common in the CF population Treatment is usually initiated based on assessment of lung function including spirometry results, chest radiograph, signs of infection, respiraty symptoms and changes in volume colour of sputum. Courses are generally given f two weeks. Response to treatment should be assessed at the end of the course earlier if required (e.g. adverse effect wsening symptoms). A third week of treatment may be considered if there has been a partial response. Po response requires review of treatment. Local practice is to withhold nebulised antibiotics during a course of Intravenous IV antibiotics to avoid toxicity. Long-term azithromycin should usually be continued during a course of antimicrobial treatment unless there are any specific interactions. 1
2 Infusions of beta-lactam antibiotics There is emerging evidence that suggests administration of beta-lactam antimicrobials by infusion is me efficacious than giving by bolus injection. It is thought this is because giving slowly results in a much better pharmacokinetic profile. F bacteriostatic drugs such as betalactams constant levels are me desirable than high peaks and low troughs. Consideration should be given to dering beta-lactam infusion on the in-patient drug chart f patients on the respiraty ward who are considered to be seriously ill and not suitable f home. Bolus injections are still appropriate f home IV administration. These guidelines have been produced by a wking group including the Scottish Adult Cystic Fibrosis team, pharmacy and microbiology departments. They are intended to be used along side national guidance such as Antibiotic Treatment f Cystic Fibrosis, 3 rd Edition, May 2009, Cystic Fibrosis Trust and local expertise. [ The group will carry out surveillance and audit of new acquisitions of SABs, MRSA, C. difficile, Pseudomonas aeruginosa (PA). This will include moniting incidence, contamination of samples, patterns of infection, resistance and audit of infection control policies, PA and MRSA eradication outcomes. These guidelines will be regularly updated and reviewed in line with emerging evidence, change in practice and results of surveillance and audits. Members of the Adult CF Microbiology wking group as below. Dr Ian Laurenson, Consultant Microbiologist Profess Andrew Greening, Consultant Physician Dr Alastair Innes, Consultant Physician Dr Helen Rodgers, Clinical Direct of Adult CF Service Catriona McMullen, Cystic fibrosis nurse specialist Douglas McCabe, Pharmacist, Cystic Fibrosis Ratified by: Antimicrobial Team and LUHD Drug and Therapeutics Committee Date written: June 2011 Date updated: September 2013 (Version 2) Review date: September
3 Table of contents Antibiotic guideline in Adult Cystic Fibrosis... 1 Table of contents Common gram-positive infections Methicillin resistant Staphylococcus aureus (MRSA) Pseudomonas aeruginosa Other gram-negative infections Fungal infections Non-tuberculous mycobacteria TIVAD infection Oral Antimicrobials Dosing Intravenous Antimicrobials Dosing Diluents and flushes Desensitisation Recommended doses in renal impairment Cost of commonly prescribed antimicrobials and serum concentration assays Summary of antimicrobial choices in adult CF
4 1. Common gram-positive infections Two agents should be used guided by patients individual tolerances and susceptibility results. See notes above f further advice. Colonising ganisms Recommended therapy Notes Haemophilus influenzae and Staphylococcus aureus Mild symptoms Co-amoxiclav 625mg every 8 ally Plus Ciprofloxacin 500mg every 8 ally Penicillin allergy: Doxycycline 100mg every 12 ally Clarithromycin 500mg every 12 ally Plus Ciprofloxacin 750mg every 12 ally Co-amoxiclav covers both H influenzae and S aureus. Ciprofloxacin covers H influenzae and P aeruginosa which is useful where P aeruginosa is grown intermittently and to reduce the risk of P aeruginosa super-infection which can be unmasked by treatment with a single anti-staphylococcal agent. Ciprofloxacin may not be required in mild exacerbations where there is little no risk previous histy of P aeruginosa infection. Moderate severe symptoms, failure of first line therapy Cefuroxime 1.5g every 8 IV Plus Ciprofloxacin 500mg every 8 ally Cefriaxone IV may be useful f patients self-administering at home as it can be given as 2g once daily (as 2 x 1g bolus injections). However, it does not have as good Staph. aureus cover as cefuroxime. 4
5 2. Methicillin resistant Staphylococcus aureus (MRSA) Eradication should include a combination of systemic (2a), topical therapy (2b) and environmental decontamination from the start. Two agents should be used guided by patients individual tolerances and susceptibility results. See notes above f further advice. 2a. MRSA Eradication 1 st line: 6 weeks al therapy. 2 nd line: 6 weeks al therapy Recommended therapy Doxycycline 100mg every 12 ally Plus Trimethoprim 200mg every 12 ally Rifampicin [dose per kg, see table 8] ally Sodium fusidate 500mg every 12 ally Rifampicin + sodium fusidate, if sensitive. TWO agents based on sensitivities. Notes Choice should be based on full sensitivities (call microbiology if full rept not available). Repeat MRSA screening as per NHS Lothian Infection Control Policy. If MRSA persists, proceed to 2 nd line treatment. Most evidence f combination of rifampicin + sodium fusidate but this combination can be poly tolerated. Up to 3 to 6 months can be given f treatment resistant cases. Anti-emetic cover may be useful. *Remember to check interactions and monit LFTs with rifampicin and sodium fusidate. 2b. MRSA decolonisation and suppression: Topical Therapy Determine mupirocin sensitivity BEFORE starting treatment (check with microbiology). At each step decolonisation should be prescribed as per currently NHS Lothian Infection Control Policy. This includes: 5 days topical treatment of nose, throat and body. Environmental decontamination. Screening close contacts in the household 5
6 Change nebuliser equipment and disinfect equipment as per manufacturer guidelines at start of treatment. See current LUHD Infection Control Manual MRSA Decolonisation / Suppression Regimen on intranet f details: MRSA treatment and outcomes should be audited on an ongoing basis and guidance updated as new evidence emerges. If samples become negative, regard patients as potential carriers f at least 6 months. At least 3 negative screens over 6 months required to confirm successful eradication. Screening should be as per current NHS Lothian Infection Control Manual. 2.c MRSA Treatment Oral treatment Intravenous treatment Recommended therapy Doxycycline 100mg every 12 ally Plus Trimethoprim 200mg every 12 ally Rifampicin [based on body weight, [see Table 8] ally Sodium fusidate 500mg every 12 ally Include an al agent from above and Vancomycin IV f 2 weeks [see guideline] Notes The role of linezolid remains unclear. It is costly and there are concerns about toxicity with prolonged treatment. FBC should be monited weekly to check f bone marrow suppression; and a maximum of 4 weeks is recommended; check interactions; counsel patient to rept any symptoms of visual impairment immediately as risk of optic neuropathy. Interactions should also be checked. NB. linezolid is an alert antibiotic and is not currently approved f any indication. An alert antibiotic fm, approved by a microbiologist and non-fmulary fm (signed by consultant and pharmacist) are required to obtain supply. Some centres have repted success with nebulised vancomycin. This is currently an experimental option. Teicoplanin 10mg/kg to nearest 200mg (max. 800mg) 12 hourly f 3 doses then every 24 IV f 2 weeks 6 Teicoplanin is given by IV bolus, so is suitable f Home IV Antimicrobial Treatment. Doses > 800mg should be given by sequential boluses over at least 10 minutes. Determination of teicoplanin serum concentrations are recommended in CF; suggested target is >20mg/L (contact microbiology lab to arrange).
7 3. Pseudomonas aeruginosa Two agents should be used guided by patients individual tolerances and susceptibility results. See notes above f further advice. 3a. Pseudomonas aeruginosa eradication Recommended therapy 1 st choice Ciprofloxacin 750mg every 12 ally Plus Tobramycin 300mg every 12 nebulised f 4 weeks 2 nd choice Ciprofloxacin 750mg every 12 ally Plus Colistimethate sodium 2MU every 12 nebulised f 6 weeks Continue f a further 6 weeks if sputum remains positive. Notes Recheck sputum at 6 weeks. Stop treatment if negative. Continue f 3 months if remains positive. 3 negative samples required, over 6 months to confirm successful eradication. Test dose of nebulised antibiotics required befe commencing treatment. After two failed attempts at eradication, give two weeks of suitable intravenous antimicrobial therapy followed by a further course of eradication therapy including nebulised tobramycin. After multiple failures, patient is likely to be colonised. See table 3c f long term suppressive therapy. Failure of eradication current exacerbation Intravenous antibiotics f 2 weeks Then Ciprofloxacin 750mg every 12 ally Plus Tobramycin 300mg every 12 nebulised f 4 weeks 7
8 3b. Pseudomonas aeruginosa exacerbation Oral treatment Recommended therapy Co-amoxiclav 625mg every 8 ally Plus Ciprofloxacin 500mg every 8 ally Notes Co-amoxiclav covers Haemophilus influenzae and Staphylococcus aureus which will also be present. Levofloxacin is approved as an alternative quinolone where ciprofloxacin is not tolerated. Intravenous treatment Ceftazidime [based on weight, see Table 9] IV Piperacillin/tazobactam 4.5g every 8 30min IV infusion as in-patient; IV bolus f home patients Aztreonam 2g every 8 IV Meropenem 2g every 8 IV Plus either Tobramycin [see guideline] IV Colistimethate sodium 2MU every 8 IV Combination of beta-lactam with tobramycin colistimethate sodium is synergistic. Initial tobramycin dose should be based on the current Tobramycin Dosing Guideline f adult CF the dosage regimen that was previously identified as suitable f the patient. Determination of serum concentrations is required - see guideline f details. Avoid prolonged regular courses of tobramycin due to risk of accumulation in the inner ear. Consider prescribing colistimethate sodium on alternate courses where regular IV tobramycin is required in der to limit ototoxicity if sensitivities allow. Note colistimethate sodium is also renally toxic and neurotoxic (usually dose related). There is some evidence that a combination of ceftazidime + meropenem are effective where both tobramycin and colistimethate sodium are not suitable e.g. due to renal toxicity. Multiple allergies multiresistant PA Fosfomycin 4g every 8 IV infusion Add as replacement f either a beta-lactam, tobramycin colistimethate sodium as a third agent where multiple allergies and/ multi-resistant Pseudomonas are a problem. Pseudomonas are usually resistant, so synergy testing should be used to confirm activity with another drug. It may be particularly useful f Liverpool strain, which has inherent resistance to most usual options. This is an unlicensed medicine, ask pharmacist f further advice
9 3c. Pseudomonas aeruginosa chronic infection Step 1 Step 2 Recommended therapy Azithromycin 500mg THREE times weekly ally Colistimethate sodium every 12 nebulised inhaled Tobramycin every 12 nebulised inhaled alternate months Notes Check LFT s befe starting treatment and every 6 months. Avoid single macrolide in presence of non-tuberculous mycobacteria to reduce the risk of resistance. Test dose of inhaled antibiotics is required befe commencing treatment. Withhold nebulised antibiotic during courses of intravenous antibiotics to limit risk of cumulative toxicity. Both colistimethate sodium and tobramycin are available as dry powder inhalers and nebulised treatment. Dry powder inhalers are generally me convenient f patients and do not require equipment and cleaning. Please follow shared care protocols available on the Lothian Joint Fmulary website: 9
10 4. Other gram-negative infections Two agents should be used guided by patients individual tolerances and susceptibility results. See notes above f further advice. When Pseuodomonas a. is also present 3 agents may be required to cover multiple pathogens. Seek advice if required. 4a. Burkholderia cepacia complex Oral treatment Recommended therapy Co-trimoxazole 960mg every 12 ally plus Minocycline 100mg every 12 ally Chlamphenicol 500mg every 6 ally Intravenous treatment Ceftazidime [based on weight, see table 9] IV Piperacillin/tazobactam 4.5g every 8 30min IV infusion as in-patient; IV bolus f home patients Meropenem 2g every 8 IV Temocillin 2g every 12 IV Notes B. cepacia species is inherently resistant to most anti-pseudomonal penicillins, aminoglycosides and colistimethate sodium. Typing required samples sent to reference lab. Synergy should be checked once a year. Oral chlamphenicol is expensive and requires moniting of FBC f bone marrow toxicity. Irreversible aplastic anaemia repted. Prolonged repeated courses should be avoided. Trimethoprim 200mg every 12, may be a suitable alternative where co-trimoxazole is not tolerated. Desensitisation may be considered where rash has occurred. Co-infection with P. aeruginosa: Regimen should include at least 2 active agents to cover both P. aeruginosa and B. cepacia (3 me agents may be required). This usually includes a combination of a beta-lactam plus tobramycin colistimethate sodium and one other agent (which can be given ally). 10
11 4b. Stenotrophomonas maltophilia Oral treatment Intravenous treatment **Seek seni advice** Recommended therapy Co-trimoxazole 960mg every 12 ally Minocycline 100mg every 12 ally Levofloxacin 500mg every 12 ally Co-trimoxazole 1440mg every 12 IV infusion Ticarcillin/clavulinic acid 3.2g every 6-8 IV infusion Notes Inherently resistant to most anti-pseudomonal penicillins, aminoglycosides and colistimethate sodium. Synergy should be checked once a year. Combinations of ceftazidime + tobramycin ciprofloxacin piperacillin/tazobactam + co-trimoxazole may be active. Co-trimoxazole and ticarcillin/clavulinic acid are given by infusion, see IV guidelines f details. Ticarcillin/clavulinic acid is currently not approved, non-fmulary fm required, infm pharmacist. There is little experience with 2 nd line agents but they may be useful to consider if the al route is not available, where other agents are not tolerated IV therapy is justified e.g. severe symptoms and/ hospitalised. Tigecycline IV may be useful where an IV tetracycline is required. It is an alert antibiotic and is not approved f this indication. Relevant fms are required to obtain supply. Contact pharmacy f advice
12 4c. Achromobacter (Alcaligenes) xylosoxidans Oral treatment Intravenous treatment **Seek seni advice** Recommended therapy Co-trimoxazole 960mg every 12 ally and Minocycline 100mg every 12 ally Chlamphenicol 500mg every 6 ally Piperacillin/tazobactam 4.5g every 8 30min IV infusion as in-patient; IV bolus f home patients Meropenem 2g every 8 IV Temocillin 2g every 12 IV Notes A. xylosoxidans is inherently resistant to most anti-pseudomonal penicillins, cephalospins, aminoglycosides and quinilones. Synergy should be checked once a year. Imipenem may be useful where meropenem can not be used if it is the preferred carbapenem on synergy tests. It is not currently approved in Lothian, the non-fmulary procedure should be followed. It is given by IV infusion, usually as an in-patient. Contact pharmacist f advice. 12
13 5. Fungal infections 5a. Oral candidiasis Likely ganisms Recommended therapy Notes Candida albicans 5b. ABPA (Aspergillis sp.) Presence in sputum alone does not require treatment. Consider treatment where diagnostic criteria met: acute clinical deteriation; total IgE > IU/ml; precipitins IgE antibody to A.fumigatus; new abnmalities on chest X-ray CT not cleared by standard antibiotics physiotherapy. Raised eosinophils 1 st line: Nystatin 100,000MU 1ml every 6 ally f 7 days 2 nd line: Fluconazole 50mg every 24 f 7 days ally Prednisolone 0.5mg/kg every 24 ally f 1-2 weeks. Taper dose over 2-3 months based on clinical progress. Po response as steroid-sparing agent: Add Itraconazole liquid ally 3-6 months (See table 8 on page 23 f dosing advice.) Commonly occurs with systemic steroids and/ broad spectrum antibiotics. Oral fluconazole will also cover vaginal candida. Persistent recurrent canidiasis may respond to regular antifungal treatment weekly f 4 weeks. Treatment failure recurrence should be investigated further by confirmation of ganism and sensitivities. Check interactions and LFT s befe starting antifungal treatment. Check LFTs after one month and throughout treatment. Caution in patients who are taking other hepatotoxic drugs, who have a histy of hepatotoxicity with other drugs who have pre-existing liver disease. The liquid preparation of itraconazole is better absbed than the capsules and should be taken on an empty stomach. PPI s and H2 antagonists reduce itraconazole absption significantly. Patients taking acid suppressive therapy should be advised to take itraconazole with a cola drink to provide and acid environment. Capsules may be considered where the al solution is not tolerated and should be taken after food to improve absption. Determination of itraconazole concentrations should be considered where there is an inadequate response concern about drug absption interactions patient compliance. Steady state is achieved after 2 weeks. Trough samples should be taken pre-dose. Infm microbiology befe sending samples so they can arrange transpt to reference lab. 13
14 5c. Invasive aspergillosis Seek expert advice including microbiology. 6. Non-tuberculous mycobacteria Likely ganisms Mycobacterium avium complex and Mycobacterium absessus. Notes Seek expert advice, including Scottish Mycobacteria Reference Labaty, telephone 26016, Dr Ian Laurenson Dr Ewan Olson. 7. TIVAD infection Likely ganisms Recommended therapy Notes S. aureus fungal. Treat based on blood culture. May require removal of line. Seek advice. 14
15 8. Oral Antimicrobials Dosing Drug Dose Notes Azithromycin Chronic anti-inflammaty: 500mg once daily three times per week Treatment: 250mg once daily Chlamphenicol 500mg four times daily; Ciprofloxacin Up to 1g four times daily in severe infections. 500mg three times daily 750mg twice daily 15 Monit FBC during treatment. Avoid in renal hepatic impairment. GI disturbance and optic peripheral neuritis possible. NB high-cost compared to alternatives ( per 2 weeks), so not first line. Clarithromycin 500mg twice daily Co-amoxiclav 625mg three times daily Co-trimoxazole 960mg twice daily 1440mg twice daily in severe infections especially if larger body weight. Doxycycline 100mg twice daily Flucloxacillin Treatment: 1g four times daily Prophylaxis: 1000mg twice daily Itraconazole liquid 5mg/kg daily See notes above. <40kg 100mg twice daily Consider checking serum concentration if po 40-59kg 150mg twice daily response absption issue e.g. on PPI. >60kg 200mg twice daily Check interactions and monit liver function. Levofloxacin 500mg twice daily Linezolid 600mg twice daily Monit FBC if > 28 day treatment. Minocycline 100mg twice daily Rifampicin <50kg: 450mg once daily Check interactions and LFTs. > 50kg: 600mg once daily 300mg twice daily. Sodium fusidate 500mg three times daily Trimethoprim 200mg twice daily
16 9. Intravenous Antimicrobials Dosing Drug f Route Dose Max Dose Notes Reconstitution Aztreonam IV bolus 2g every 8 2g QDS Amikacin IV bolus 30mg/kg ONCE daily, up to maximum Serum concentrations required 1000mg per day initially. Ceftazidime IV bolus mg/kg daily in 2 3 divided doses. 9g over 24. BD dosing given f convenience. body wt (kg) 12 hourly 8 hourly TDS dosing dose reduction may help if < 40kg: 2-3g 1-2g intolerable nausea occurs which is resistant to 40-60kg 3g 2g antiemetics. >60kg 4g 2-3g Ceftriaxone IV bolus 2g every 24 Cefuroxime IV bolus 1.5g every 8 1.5g every 6 Colistimethate sodium (Colomycin) IV bolus < 40kg 40-60kg 1 MU every MU every 8 2 MU every 8 Consider dose reduction f mild, transient adverse effects. > 60kg 2 MU every 8 Fosfomycin IV 4g every 8 4g every 6 Dilute in 250ml infusion fluid and give over 60 infusion minutes. Meropenem IV bolus <40kg 1.5g every 8 2g TDS >40kg 2g every 8 Piperacillin/tazobactam IV bolus 4.5g every 8 4.5g every 6 Teicoplanin IV bolus 10mg/kg every 12 f 3 doses, then 10mg/kg every 24 Doses > 800mg can be given as 2 separate bolus injections. Determination of serum concentrations is useful to confirm dose is therapeutic. Trough concentrations should be > 20mg/l f treatment of MRSA. Temocillin IV bolus 2g every 12 2g every 8 Ticarcillin/clavulinic acid IV infusion 3.2g every 8 3.2g every 6 Dilute in 100mls glucose 5% water f injections and give over 30 mins. Tobramycin IV bolus 120mg/m 2 every 12 - [see guideline]. Serum concentration moniting required. Vancomycin IV infusion see guideline - 16
17 10. Diluents and flushes Drug Diluent Volume of diluent per vial Aztreonam 1g and 2g vials Water f injection 10ml Ceftazidime 1g and 2g vials Water f injection 10ml Cefriaxone 1g vials Water f injection 10ml Cefuroxime 1.5g vials Water f injection 15ml Colistimethate sodium (Colomycin) 1MU and 2MU Sodium chlide 0.9% TIVAD/Long-line: 10ml Venflon: 20-40ml Fosfomycin 4g vials Water f injection Sodium chlide 0.9% Sodium chlide 0.9% 20mls 250mls 50ml f flushing giving set Meropenem 1g vials Water f injection 20ml per 1g vial 40ml f 2g dose Piperacillin/tazobactam 4.5g vials Water f injection 20ml Temocillin 1g vials Water f injection 10ml each vial 20ml f 2g dose Teicoplanin 200mg and 400mg vials Water f injection 3mls provided with each vial Ticarcillin/clavulinic acid (Timentin ) 3.2g vials Water f injection Glucose 5% Glucose 5% Tobramycin ampoules Already in solution N/A 10mls 100mls 50ml f flushing giving set The IV line must always be flushed befe each antibiotic to avoid any interaction when drugs are mixed together. Specifically aminoglycosides and betalactams can precipitate leading to inactivation befe the drugs reach the systemic circulation, risking treatment failure. Long-line and TIVAD (Pt) Ensure that all patients are prescribed 10ml sodium chlide 0.9% flush and 4ml heparin sodium 100iu/ml to lock the line with every dose of intravenous antibiotics. Peripheral venous catheter (Venflon ) Prescribe 10ml sodium chlide 0.9% f flushing with each dose of IV antibiotic. Every patient should also have an in date Jext f use in case of anaphylaxis and be counselled on how to use it. This should be prescribed if necessary. 17
18 11. Desensitisation 11.1 Ceftazidime and aztreonam Syringe Dose administered Administration time mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes 5 5 mg in 50ml 0.9% sodium chlide 20 minutes 6 50 mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 2-3 minutes 11.2 Piperacillin/tazobactam Syringe Dose administered Administration time mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 2-3 minutes 11.3 Meropenem Syringe Dose administered Administration time mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes 5 5 mg in 50ml 0.9% sodium chlide 20 minutes 6 50 mg in 50ml 0.9% sodium chlide 20 minutes mg in 50ml 0.9% sodium chlide 20 minutes mg in 40ml 0.9% sodium chlide 2-3 minutes [made on ward] 18
19 Patients who require desensitisation should be admitted to the ward f the procedure. At least 24 notice is required f pharmacy to prepare syringes. PRE-MEDICATION: IV hydroctisone mg IV chlpheniramine 5 mg IV ranitidine 50 mg may be useful to prevent urticarial rash [unlicensed indication] Desensitisation is required f each subsequent course on antibiotics including the problem drug and after missing me than 1-2 doses. Each syringe (except the final one) is administered over minutes via a syringe pump. The final syringe is given as a slow bolus. Observations (BP, pulse, temperature) must be carried out every 15 minutes and treatment stopped if there is any sign of a reaction. ANAPHYLAXIS Adrenaline 1 in 1000 IM (follow UK resuscitation council guidelines f treatment of anaphylaxis, 0.5mls f adults, repeated at 5 minute intervals as required and tolerated), Chlpheniramine 10mg IM IV Salbutamol 5mg nebulised, f wheeze IV hydroctisone sodium succinate 200mg delayed onset of action, but can prevent further deteriation in severe cases Oxygen f hypoxia if required Mild urticaria may be successfully treated with al antihistamines and steroids which can allow treatment to continue. CONTRA-INDICATIONS Severe non-ige mediated reaction such as Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatitis haemolytic anaemia. CONTINUED DESENSITISATION AND FURTHER COURSES If desensitisation is successful, the next dose of antibiotic should be given within 8-12 and must be continued regularly at full dose to ensure maintenance of desensitisation status. Allergic reactions are still possible up to the FOURTH dose. The patient should be warned to rept any signs of a reaction immediately. Continued treatment is required to ensure desensitisation without any missed doses. If me than three consecutive doses in a course are missed, desensitisation must be repeated. References: 1. Khan D and Solensky R. Drug Allergy. J Allergy Clin Immunol 2010;125:S Burrows J, Toon M, Bell S. Antibiotic desnsitization in adults with cystic fibrosis. Respirology 2003;8: Moss R, Babin S, Hsu Y et al. Allergy to semisynthetic penicillins in cystic fibrosis. The Journal of Pediatrics 1984;104: Ghosal S and Tayl C. Intravenous desensitization to ceftazidime in cystic fibrosis patients. J Antimicrob Chemotherapy 1997;39: Wilson D, Owens R, Zuckerman J. Successful meropenem desensitization in a patient with cystic fibrosis. Ann Pharmacother 2003;37: Parmar J, Nasser S. Antibiotic allergy in cystic fibrosis. Thax 2005;60:
20 12. Recommended doses in renal impairment Use Cockroft-Gault ensure egfr is crected f BSA. Drug Dose if GFR 20-50ml/min Dose if GFR ml/min Azithromycin Dose as in nmal Dose as in nmal Aztreonam Dose as in nmal 2g stat, then 1g every 8 Ceftazidime 31-50ml/min 2g every ml/min 2g every 24 Ceftriaxone 1g every 12 Dose as in nmal. Cefuroxime 1.5g every 8 1.5g every 8-12 Cetirizine Chlamphenicol Ciprofloxacin Clarithromycin Co-amoxiclav Colistimethate sodium Dose as in nmal Dose as in nmal Dose as in nmal Dose as in nmal Dose as in nmal 1-2 MU every 8 Dose as in nmal Dose as in nmal Dose if GFR < 10 ml/min Dose as in nmal 2g stat, then 500mg every ml/min 1g every 24 Dose as in nmal. 1.5g every mg daily Dose as in nmal Dose if on haemodialysis Dose as in nmal renal function Dialysed. Dose as in GFR < 10ml/min. Dialysed. 500mg-1g every Dose as in nmal renal function. Dialysed. Dose as in GFR< 10ml/min. Not dialysed. Dose as in GFR < 10ml/min Not dialysed. Dose as in nmal mg bd 250mg bd Not dialysed mg every 12 Dose as in nmal 1MU every mg every mg tds 1MU every Oral: IV: mg bd 200mg bd Dialysed. Dose as in GFR < 10ml/min Dialysed. Dose as in GFR < 10ml/min. Not dialysed. Dose as in GFR < 10ml/min Notes May increase ciclospin levels, monit levels. <5ml/min 1g every 48 Caution with aminoglycosides as can adversely affect renal function Possibly increases ciclospin and tacrolimus levels. Monit serum chlamphenicol levels. Watch very carefully. Increased nephrotoxicity with ciclospin. Anecdotally increases tacrolimus levels. Increases ciclospin and tacrolimus levels Monit closely 20
21 Drug Co-trimoxazole (al treatment dose) Doxycycline Dose if GFR 20-50ml/min Dose as in nmal Dose as in nmal Dose if GFR ml/min Dose if GFR < 10 ml/min Dose if on haemodialysis Notes 480mg bd 480mg bd Dialysed. 480mg bd. Increased risk of nephrotoxicity with ciclospin. Monit clinical response and U+E s. Dose as in nmal Dose as in nmal Not dialysed. Dose as in Possibly increases plasma nmal. ciclospin levels Flucloxacillin Fluconazole Dose as in nmal Dose as in nmal Dose as in nmal Dose as in nmal Dose as in nmal up to a total daily dose of 4g 50% of nmal dose Not dialysed. Dose as in GFR < 10 ml/min Dialysed. Dose as in GFR < 10ml/min. Give post dialysis. Not dialysed. Dose as in nmal. Not dialysed. Dose as in nmal. Dose as in GFR<10ml/min Fusidic acid Dose as in nmal Dose as in nmal Dose as in nmal Itraconazole Dose as in nmal Dose as in nmal Dose as in nmal Levofloxacin Initial dose 500mg Initial dose 500mg Initial dose 500mg then reduce to then reduce to then reduce to 500mg every mg every mg every 48 Linezolid Dose as in nmal Dose as in nmal Dose as in nmal Dialysed. Dose as in GFR< but 10ml/min. monit renal function closely Meropenem 2g every 12 1g every 12 1g every 24 Dialysed. Dose as in GFR< 10ml/min. Rifampicin Dose as in nmal Dose as in nmal % of nmal Not dialysed. Dose as in dose GFR< 10ml/min. Piperacillin/ Dose as in nmal 4.5g every g every 12 Not dialysed. Dose as in tazobactam GFR< 10ml/min. Teicoplanin Dose as in nmal Not dialysed. Dose as in GFR< 10ml/min. Give nmal loading dose, then 10mg/kg every 48 Give nmal loading dose, then 10mg/kg every 72. Increases ciclospin and tacrolimus levels Increases ciclospin and possibly tacrolimus levels Ciclospin half-life increased by 33%, increased risk of nephrotoxicity. Monit FBC, if sign of bone marrow toxicity reduce dose to 600mg once daily. Markedly reduces ciclospin levels. Serum concentration should be monited in der to optimise dose. 21
22 Drug Ticarcillin/clavulinic acid (Timentin ) Tobramycin Trimethoprim Dose if GFR 20-50ml/min >30ml/min 3.2g every ml/min 2mg/kg then check level Dose as in nmal Dose if GFR ml/min 10-30ml/min 1.6g every ml/min 1mg/kg the check level Nmal dose f 3 days, then 50% of dose Dose if GFR < 10 ml/min 1.6g every 12 <20ml/min Avoid 50% of nmal dose every 24 Dose if on haemodialysis Not dialysed. Dose as in GFR<1ml/min. Dialysed. Dose as in GFR< 10ml/min. Dialysed. Give 50% of nmal dose every 24. Notes Risk of accumulation. Monit levels and daily and adjust dose. Monit U+E s and clinical response. 22
23 13. Cost of commonly prescribed antimicrobials and serum concentration assays IV Antibiotic Cost f 2 weeks Assay Cost Ceftriaxone <50 Itraconazole 120 Vancomycin Teicoplanin 120 Ceftazidime Tobramycin 40 Piperacillin/tazobactam Vancomycin 40 Tobramycin Colistimethate sodium Ticarcillin/clavulinic acid (Timentin) * Teicoplanin Fosfomycin * Meropenem Aztreonam Tigecycline Temocillin Oral antibiotics Doxycycline 100mg capsules 1.68 Ciprofloxacin 500mg tablets 2.07 Ciprofloxacin 750mg tablets 2.82 Clarithromycin 500mg tablets 4.27 Co-amoxiclav 625mg tablets 4.27 Co-trimoxazole 480mg tablets Minocycline 50mg tablets Levofloxacin 500mg tablets 80 Chlamphenicol 250mg capsules Linezolid 600mg tablets 28 day course: > 2500 Itraconazole liquid 200mg BD 28 days: 450 *The cost of 2 weeks of B.Braun Easypumps is approximately This is off-set against the cost of an in-patient bed (nearly 3000). 23
24 14. Summary of antimicrobial choices in adult CF Organism Haemophilus influenzae and Staphylococcus aureus (MSSA) First line ORAL treatment Co-amoxiclav 625mg tds ally +/- Ciprofloxacin $ 500mg tds ally Second line IV treatment Penicillin allergy: Doxycycline $ 100mg bd ally Clarithromycin $ 500mg bd ally +/- Ciprofloxacin $ 750mg bd ally Intravenous treatment: Cefuroxime 1.5g every 8 IV ( ceftriaxone 2g every 24 IV at home) + Ciprofloxacin $ 500mg tds ally Length of treatment 7 14 days Staphylococcus aureus (MRSA) Pseudomonas aeruginosa Doxycycline $ 100mg bd ally Trimethoprim 200mg bd ally Rifampicin $ <50kg 450mg od, >50kg 300mg bd ally Sodium fusidate 500mg bd-tds ally Co-amoxiclav 625mg tds ally +/- Ciprofloxacin $ 500mg tds ally Intravenous treatment: Vancomycin [see guideline] IV Teicoplanin IV Third line: Linezolid $ 600mg bd ally Ceftazidime 2-3g tds 3-4g bd IV (use higher dose f >60kg) Piperacillin/tazobactam* 4.5g tds IV Aztreonam 2g tds IV Meropenem 2g tds IV Plus Tobramycin [see guideline] IV Colistimethate sodium 2MU tds IV (<60kg reduce dose to 1.5MU tds) 14 days Check sensitivities at each stage, call lab if not available. 14 days Burkholderia cepacia Stenotrophomonas maltophilia Achromobacter xylosoxidans ABPA (Aspergillus sp.) Co-trimoxazole $ 960mg bd ally + Minocycline $ 100mg bd ally Chlamphenicol 500mg qds ally Co-trimoxazole $ 960mg bd ally Co-trimoxazole $ 960mg bd ally Minocycline $ 100mg bd ally Chlamphenicol 500mg qds ally Prednisolone 0.5mg/kg od >60kg: 30mg 50-59kg: 25mg <50kg: 20mg Taper accding to response over 2-3 months. Alert antibiotic, please fill out Alert Antibiotic Moniting Fm. $ Significant drug interactions, check drug histy befe prescribing. * Given by IV infusion, see main guide f volumes and rates. 3 rd line: Fosfomycin* 4g tds IVI Ceftazidime 2-3g tds 3-4g bd IV (use higher dose f >60kg) Piperacillin/tazobactam* 4.5g tds IV Meropenem 2g tds IV Temocillin 2g bd tds IV Minocycline $ 100mg bd ally Levofloxacin $ 500mg bd ally Piperacillin/tazobactam* 4.5g every 8 IV Meropenem 2g every 8 IV Temocillin 2g bd tds IV Po response: add Itraconazole $ liquid >60kg: 200mg bd 40-59kg: 150mg bd <40kg: 100mg bd Serum levels can be obtained if po absption is suspected. 14 days 14 days 14 days 3-6 months 24
Antibiotic guideline in Adult Cystic Fibrosis
Antibiotic guideline in Adult Cystic Fibrosis Choice of antibiotics in cystic fibrosis is based on several facts including ganism sensitivity, histy of adverse reactions allergy and severity of symptoms.
More informationIntravenous Antibiotic Therapy Information Leaflet
Scottish Adult Cystic Fibrosis Service Ninewells Hospital Dundee Intravenous Antibiotic Therapy Information Leaflet February 2008 Intravenous antibiotic therapy in cystic fibrosis Patients with cystic
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE
ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE Version 1.0 Date ratified June 2009 Review date June 2011 Ratified by Authors Consultation Nottingham Antibiotic Guidelines Committee
More informationPatients. Excludes paediatrics, neonates.
Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All
More informationConsider the patient, the drug and the device how do you choose?
Consider the patient, the drug and the device how do you choose? Tim Hills Lead Pharmacist Antimicrobials and Infection Control Nottingham University Hospitals NHS Trust OPAT Recommendations Drug Therapy
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationSepticaemia Definitions 1
Septicaemia Definitions 1 Term Definition Bacteraemia Systemic Inflammatory response (SIRS) Sepsis Bacteria that can be cultured from the blood stream The systemic response to a wide range of stresses.
More information- the details, where possible, of the antibiotic products these companies supply or have supplied.
Under the Freedom of Information Act 2000 please could you provide me with a list of all companies currently supplying antibiotics - or that have supplied antibiotics in the last three years - to Royal
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationIntro Who should read this document 2 Key practice points 2 Background 2
Antibiotic Guidelines: Obstetric Anti-Infective Prescribing Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Kelly Alexander / Frances Garraghan
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationTreatment of peritonitis in patients receiving peritoneal dialysis Antibiotic Guidelines. Contents
Treatment of peritonitis in patients receiving Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Jude Allen (Pharmacist) Additional author(s): Dr David Lewis, Dr Dimitrios Poulikakos,
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationProtocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT
CONTROLLED DOCUMENT Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Guideline Clinical The purpose
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationCystic Fibrosis- management of Burkholderia. cepacia complex infections
Guideline Cystic Fibrosis- management of Burkholderia cepacia complex infections Key messages Burkholderia cepacia infections are associated with significant adverse outcomes in Cystic Fibrosis patients
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationAntibiotic Prophylaxis in Adult Orthopaedic Surgery. Formulary/prescribing guideline
Document type: Antibiotic Prophylaxis in Adult Orthopaedic Surgery Version: 2.0 Author (name): Author (designation): Validated by Formulary/prescribing guideline Dr Celia Chu, Dr Katy Edwards, Dr Pradeep
More informationSpeciality: Therapeutics
Gentamicin Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission May 2017 Date on which
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationNational Antimicrobial Prescribing Survey
Indication documented Surgical prophylaxis >24 hrs Allergy mismatch Microbiology mismatch Incorrect route Incorrect dose/frequency Incorrect duration Therapeutic Guidelines Local guidelines * Non-compliant
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationTo guide safe and appropriate selection of antibiotic therapy for Peritoneal Dialysis patients.
Nephrology Directorate Subject: Objective: Prepared by: Aintree Antibiotic Guidelines for Peritoneal Dialysis (PD): Catheter Insertion, and the Diagnosis and Treatment of PD Peritonitis and Exit-Site Infections.
More informationFOLLOWING BUNDLE ADMINISTERED WITHIN ONE HOUR.
Patient label DATE and TIME: 1 REVIEW BY Emergency Department SENIOR REGISTRAR (ED BLEEP 5999) +/-Leave Proforma 2 FOLLOWING BUNDLE ADMINISTERED WITHIN ONE HOUR. Bloods for FBC, U+E, CRP, LFT s, Clotting
More informationAntimicrobial Update Stewardship in Primary Care. Clare Colligan Antimicrobial Pharmacist NHS Forth Valley
Antimicrobial Update Stewardship in Primary Care Clare Colligan Antimicrobial Pharmacist NHS Forth Valley Setting the Scene! Consequences of Antibiotic Use? Resistance For an individual patient with
More informationAcute Pyelonephritis POAC Guideline
Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationGuidelines for the Empirical Treatment of Sepsis in Adults (excluding Neutropenic Sepsis)
Guidelines for the Empirical Treatment of Sepsis in Adults (excluding Neutropenic Sepsis) Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state
More informationWomen s Antimicrobial Guidelines Summary
Women s Antimicrobial Guidelines Summary 1. Introduction and Who Guideline applies to This guideline has been developed to deliver safe and appropriate empirical use of antibiotics for patients at University
More informationDiagnosis: Presenting signs and Symptoms include:
PERITONITIS TREATMENT PROTOCOL CARI - Caring for Australasians with Renal Impairment - CARI Guidelines complete list ISPD Guidelines: http://www.ispd.org/lang-en/treatmentguidelines/guidelines Objective
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS
ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS Contents 1. How to I calculate a gentamicin dose?... 2 2. How do I prescribe gentamicin on the cardex?... 2 3. Can I give
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationGUIDELINES FOR IV TO ORAL SWITCH FOR ANTIBITOICS
Index No: MMG51t GUIDELINES FOR IV TO ORAL SWITCH FOR ANTIBITOICS Version: 1.0 Date ratified: June 2017 Ratified by: (Name of Committee) Director Lead (Trust-wide policies) Associate Medical Director (local
More informationGuidelines for Antimicrobial treatment for treatment of confirmed infections adults
Guidelines for Antimicrobial treatment for treatment of confirmed infections adults This guideline gives recommendations for treatment of confirmed infections in adults for children please see the Paediatric
More informationDRAFT DRAFT. Paediatric Antibiotic Prescribing Guideline. May
Paediatric Antibiotic Prescribing Guideline www.oxfdahsn.g/children Magdalen Centre Nth, 1 Robert Robinson Avenue, Oxfd Science Park, OX4 4GA, United Kingdom t: +44(0) 1865 784944 e: info@oxfdahsn.g Follow
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationThis controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245. This controlled document
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationPVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust
PVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust Neonatal Case History Neonate born at 26 +2 gestation Spontaneous onset of
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required
More informationAntibiotic Guideline: Empirical Treatment of Bone and Joint Infection in Adults
Antibiotic Guideline: Empirical Treatment of Bone and Joint Infection in Adults Document type: Prescribing guideline Version: 5.0 Author (name and designation) Samim Patel, Antimicrobial Lead Pharmacist
More informationJoint Trust Guideline for the Antibiotic Management of Diabetes Related Foot Infections in Adults
Joint Trust Guideline for the Antibiotic Management of Diabetes Related Foot Infections in Adults A clinical guideline recommended For use in: Clinical areas treating patients with diabetes related foot
More informationNottingham Renal and Transplant Unit
Nottingham Renal and Transplant Unit Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out
More informationTrust Guideline for the Management of: Antibiotic Prophylaxis in adults undergoing procedures in Interventional Radiology
Antibiotic Prophylaxis in adults undergoing procedures in Interventional Radiology A Clinical Guideline For use in: By: For: Division responsible for document: Key words: Interventional Radiology Prescribers
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationRole of IV Therapy in Bone and Joint Infection
Role of IV Therapy in Bone and Joint Infection Andrew Seaton ID Consultant, Queen Elizabeth University Hospital Lead Doctor Antimicrobial Management Team, NHS GGC @raseaton66 OPAT The IVnOAT Perspective
More informationSURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS
SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationI am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Antibiotics.
Ref: FOI/CAD/ID 3459 27 June 2017 Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of Information Act
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationNHS Dumfries And Galloway. Surgical Prophylaxis Guidelines
NHS Dumfries And Galloway Surgical Prophylaxis Guidelines The aim of surgical prophylaxis is to reduce rates of surgical site and health-care associated infections and so reduce surgical morbidity and
More informationCLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:
CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by
More informationInfection Comments First Line Agents Penicillin Allergy History of multiresistant. line treatment: persist for >7 days they may be
Gastrointestinal Infections Infection Comments First Line Agents Penicillin Allergy History of multiresistant Campylobacter Antibiotics not recommended. Erythromycin 250mg PO 6 Alternative to first N/A
More informationyour hospitals, your health, our priority PARC (Policy Approval and Ratification Committee) STANDARD OPERATING PROCEDURE:
STANDARD OPERATING PROCEDURE: TRUST ANTIBIOTIC TREATMENT SOP SOP NO: TW10/136 SOP 1 VERSION NO: VERSION 6.1 (JANUARY 2013) APPROVING COMMITTEE: INFECTION PREVENTION AND CONTROL COMMITTEE DATE THIS VERSION
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationVolume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000.
Volume 8; Number 22 LINCOLNSHIRE GUIDELINES FOR THE TREATMENT OF COMMONLYY OCCURRING INFECTIONS IN PRIMARY CARE: WINTER 2014/15 In this issue of the PACE Bulletin we present an update of our Guidelines
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationSEPTEMBER 2017 DRUG ANTIBIOTICS COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
SEPTEMBER 2017 DRUG ANTIBIOTICS This optimal usage guide is mainly intended f primary care health professionnals. It is provided f infmation purposes only and should not replace the clinician s judgement.
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationWho should read this document 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version 3. Policy/Procedure/Guideline 3
Antibiotic Prophylaxis in Cranial Neurosurgery Antibiotic Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationOral antibiotics are not always straight forward
Oral antibiotics are not always straight forward OPAT Regional Workshop 1 st May 2018 Fiona Robb, Antimicrobial Pharmacist NHS Greater Glasgow & Clyde Introduction Describe NHS GGC s Oral vs IV Antibiotics
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationUpdated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007
Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationTreatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals
Treatment of Surgical Site Infection Meeting Quality Statement 6 Prof Peter Wilson University College London Hospitals TEG Quality Standard 6 Treatment and effective antibiotic prescribing: People with
More informationAmoxicillin Introduction: Mechanism of action: Pharmacology: Indications: Dosage: 12 Weeks ( 3 Months):
Amoxicillin Introduction: A semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microganisms. Mechanism of action:
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More informationUPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM
UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationCell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification
Cell Wall Weakeners Antimicrobials: Drugs that Weaken the Cell Wall Beta Lactams Penicillins Cephalosporins Carbapenems Aztreonam Vancomycin Teicoplanin Bacterial Cell Wall Bacterial cytoplasm is hypertonic
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationPharmaceutical issues relating to STI s. June Minton Lead HIV/GUM & Infectious Diseases Pharmacist University College London Hospitals NHS Trust
Pharmaceutical issues relating to STI s June Minton Lead HIV/GUM & Infectious Diseases Pharmacist University College London Hospitals NHS Trust Objectives Treatment options for syphilis, LGV, TV, gonorrhoea
More information